A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [^177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)
Latest Information Update: 12 Feb 2025
Price :
$35 *
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Octreotide
- Indications Gastric cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms NETTER-3
- Sponsors Novartis Pharmaceuticals
- 24 Jan 2025 New trial record